KRAS and non-small cell lung carcinoma: In a conditional Kras-driven genetically engineered mouse model (GEMM) of non-small-cell lung carcinoma (NSCLC), treatment with radiotherapy and an anti-PD1 antibody resulted in significant volume reduction (up to 70%) of the target lesion, and durable tumor regression (up to 12 weeks), along with an increase in inhibitory T cell markers [182].